tradingkey.logo

Viatris Announces Positive Top-Line Results From Two Pivotal Phase 3 Studies Of Novel Fast-Acting Meloxicam (Mr-107A-02) For The Treatment Of Moderate-To-Severe Acute Pain

ReutersMay 8, 2025 10:56 AM

- Viatris Inc VTRS.O:

  • VIATRIS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM TWO PIVOTAL PHASE 3 STUDIES OF NOVEL FAST-ACTING MELOXICAM (MR-107A-02) FOR THE TREATMENT OF MODERATE-TO-SEVERE ACUTE PAIN

  • VIATRIS INC: ALL PRIMARY AND SECONDARY ENDPOINTS WERE MET IN BOTH PHASE 3 STUDIES

  • VIATRIS INC: TARGETING NEW DRUG APPLICATION SUBMISSION TO U.S. FDA BY END OF 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI